These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12425359)

  • 1. Novel insights on high-density lipoprotein in coronary heart disease.
    Genest J
    Int J Clin Pract Suppl; 2002 Oct; (132):17-22. PubMed ID: 12425359
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel targets that affect high-density lipoprotein metabolism: the next frontier.
    Davidson MH; Rosenson RS
    Am J Cardiol; 2009 Nov; 104(10 Suppl):52E-7E. PubMed ID: 19895945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of high-density lipoprotein cholesterol in atherothrombosis.
    Choi BG; Vilahur G; Viles-Gonzalez JF; Badimon JJ
    Mt Sinai J Med; 2006 Jul; 73(4):690-701. PubMed ID: 16878275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors?
    Brinton EA; Nanjee MN; Hopkins PN
    J Am Coll Cardiol; 2004 Jun; 43(12):2233-5. PubMed ID: 15193685
    [No Abstract]   [Full Text] [Related]  

  • 6. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein as a therapeutic target: a peep into the future.
    Jain P
    Indian Heart J; 2006; 58(4):350-1. PubMed ID: 19039154
    [No Abstract]   [Full Text] [Related]  

  • 9. High-density lipoprotein cholesterol and coronary heart disease.
    Young CE; Karas RH; Kuvin JT
    Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials.
    Brown BG; Stukovsky KH; Zhao XQ
    Curr Opin Lipidol; 2006 Dec; 17(6):631-6. PubMed ID: 17095907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The science behind statins and fibrates.
    Fruchart JC
    Int J Clin Pract Suppl; 2002 Oct; (132):11-6. PubMed ID: 12425358
    [No Abstract]   [Full Text] [Related]  

  • 13. Nicotinic acid and the prevention of coronary artery disease.
    Digby JE; Lee JM; Choudhury RP
    Curr Opin Lipidol; 2009 Aug; 20(4):321-6. PubMed ID: 19494772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperlipidemia and cardiovascular disease: should we abandon HDL cholesterol as a therapeutic target in coronary heart disease.
    Nofer JR
    Curr Opin Lipidol; 2010 Aug; 21(4):392-3. PubMed ID: 20625261
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease.
    Kiliszek M; Maczewski M; Styczyński G; Duda M; Opolski G; Beresewicz A
    Coron Artery Dis; 2007 May; 18(3):201-9. PubMed ID: 17429294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
    Marcil M; O'Connell B; Krimbou L; Genest J
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events.
    Fonarow GC; Watson KE
    Am Heart J; 2004 Jun; 147(6):939-41. PubMed ID: 15199335
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate].
    Kaletha K; Chodorowski Z; Anand IS; Rybakowska I; Nagel-Starczynowska G
    Przegl Lek; 2003; 60(4):223-5. PubMed ID: 14569888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.